Randomized Study to Assess the Effect of Thrombus Aspiration on Flow Area in ST-Elevation Myocardial Infarction Patients: an Optical Frequency Domain Imaging Study  by unknown
FEATURED CLINICAL RESEARCH
SAT-TAVI (Single Antiplatelet Therapy for TAVI) study: A Randomized Study
Comparing double to single antiplatelet therapy for Transcatheter Aortic Valve
Implantation
Eugenio Stabile, Giovanni Sorropago, Armando Pucciarelli, Linda Cota, Vittorio
Ambrosini, Lugi Salemme, Marco Agrusta, Paolo Rubino
Background: The use of transcatheter aortic-valve implantation (TAVI) has been
shown to reduce mortality among high-risk patients with aortic stenosis who are not
candidates for surgical replacement. TAVI is performed via the trans-femoral (TF-
TAVI) route as the first choice delivery approach with encouraging results from
randomized trials and worldwide registries. Bleedings and vascular complications are
the most common are common adverse events after TF-TAVI procedure. Available
reports recommend to prescribe double antiplatelet therapy after TAVI. Significant
debate remains, however, with regard to the correlation between the effects of double
or single antiplatelet therapy and ensuing ischemic and hemorrhagic complications.
Aim of this randomized trial is to evaluate safety and efficacy of single vs double
antiplatelet therapy after TAVI. 
Methods: From January 2009 to March 2011, a total of 142 patients in our institutions
underwent TF-TAVI. Patients should have been on aspirin therapy and were randomly
assigned to Thienopiridine Arm (Clopidogrel 75 mg/day or Ticlopidine 250 mg/Bid)
or No Thienopiridine arm.Patients received a detailed clinical assessment and serial
blood testing before and 1 hour, 24 four, 48 eight hours and at discharge after TAVI.
At one month patients underwent a clinical/Echographic follow up visit. Bleedings,
vascular complications, neurologic events valve failures and any other potential adverse
event were classified according to the VARC criteria.
Results: Six months results will be presented at the meeting. Primary endpoint will be
30 days mortality. As secondary endpoints will be considered 30 days bleedings, 30
days MACCE, 6 months valve failures and 6 months neurologic events.
Conclusion: This randomized study will provide a clear indication on the opportunity
to adopt a single vs. double antiplatelet regimen for TAVI.
Hetero Drug-Eluting Stent Implantation (Switch Strategy) for Patients with
Drug-Eluting Stent Restenosis: Final Results From the Prospective Multicentre
Spanish Registry
Fernando Alfonso, Maria J. Perez-Vizcayno, Jaime Dutary, Javier Zueco, Vicens
Marti, Jose M Hernandez, Iñigo Lozano, Jose R Lopez-Minguez, Juan Angel, Angel
Cequier, Raul Moreno, Arturo Garcia-Touchard, Luis Martinez-Elbal, Rafael
Melgares, Cristina Fernandez, Rosana Hernandez
Background: Treatment of patients with drug-eluting stent (DES) in-stent restenosis
(ISR) remains a challenge. We sought to assess the effectiveness of a hetero DES
strategy in patients with DES ISR.
Methods: The RIBS-III study was a prospective, multicentre, study aimed to assess
results of coronary interventions in patients with DES ISR. Hetero-DES implantation
was the recommended strategy. The primary angiographic end-point was minimal
lumen diameter at late follow-up. The main clinical outcome measure was a composite
of cardiac death, myocardial infarction and target lesion revascularization.
Results: 363 consecutive patients with DES ISR from 12 sites in Spain were included.
The hetero-DES strategy was used in 274 patients (75%) and a different therapeutic
modality (no hetero-DES) was used in 89 patients (25%) (homo-DES [n=51], bare-
metal stent [n=9], balloon angioplasty [n=29]). Baseline characteristics were similar in
the 2 groups although time to ISR tended to be shorter and lesion length was longer in
the hetero-DES group. At late angiographic follow-up (median 278 days, 77% of
eligible patients) minimal lumen diameter was larger (1.86±0.7 vs
1.40±0.9 mm, p=0.003) and recurrent restenosis rate lower (22% vs 40%, p=0.008) in
the hetero-DES group. At last clinical follow-up (99% of patients, median 771 days)
event-free survival was superior 77% vs 65%, p=0.039) in the hetero-DES group, as a
result of a lower requirement for target lesion revascularization (19% vs 29%, p=0.06).
After adjustment for confounders using protensity score analysis, minimal lumen
diameter (p=0.001) the restenosis rate (RR 0.41, 95%CI 0.21-0.80, p=0.01) and the
event-free survival (HR 0.56 95%CI 0.33-0.96, p=0.038) remained significantly
improved in the hetero-DES group.
Conclusion: In patients with DES ISR a hetero-DES strategy provides superior late
clinical and angiographic results as compared with alternative interventional
modalities.
2-year results of the subclavian access for TAVI with the CoreValve
bioprosthesis
Anna S. Petronio, Marco De Carlo, Cristina Giannini, Francesco Bedogni,
Francesco Maisano, Federica Ettori, Silvio Klugmann, Arnaldo Poli, Antonio
Mazzocchi, Angelo Ramondo, Gennaro Santoro, Gian Paolo Ussia
Background: Our aim was to assess the safety and efficacy of the subclavian approach
as compared with the transfemoral
Methods: 141 patients who underwent TAVI with The subclavian approach were case
matched with 141 patients who underwent TAVI with the conventional transfemoral
approach.
Results: The subclavian approach was used in 141 patients. . Propensity score analysis
was used to identify and match a control group of patients (n=141) who underwent
TAVI with the conventional transfemoral approach. The rate of peripheral artery disease
was significantly higher in the subclavian vs. femoral group (85.1% vs. 20.6%,
P<0.0001). Device success was 97.9% vs. 96.5% in the subclavian vs. femoral groups,
(P=0.47), with intraprocedural mortality of 1.4% vs. 0.7% (P=0.56). The most common
in-hospital complications were a new left bundle branch block (32.6% vs. 35.5%,
subclavian vs. femoral, P=0.61), and the need for pacemaker (24.1% vs. 23.4%,
P=0.88). The rate of acute renal failure (stage III) was higher in the femoral approach
(5.3% vs. 14.3%, P=0.02 subclavian vs. femoral). The incidence of major and minor
vascular complications were similar in the two groups of patients (1.4% vs. 4.3%,
P=0.15 and 12.1% vs. 9.9%, P=0.56 subclavian vs. femoral) with only two specific
serious complications for the subclavian access (subclavian dissection). The rate of
suboptimal CoreValve deployment was 13.5% vs. 14.2%, subclavian vs. femoral,
P=0.81. The learning curve for the subclavian approach lead to a lower use of general
anesthesia after the first 4 cases (from 74.4% to 44.9%; P=0.001) without affecting
procedural success and duration. The 30-day combined safety endpoint was 16.3% in
the subclavian group and 19.9% in the femoral group (P=0.43). In the subclavian and
femoral groups, actuarial survival was 82.8±3.5% vs. 83.3±3.4% (P=0.92), freedom
from cardiac death was 89.1±2.8% vs. 92.5±2.2% (P=0.36), and freedom from
combined safety endpoint was 83.9±3.8% vs. 78.7±4.2% (P=0.97).
Conclusion: The subclavian approach is a feasible and safe option for TAVI, providing
excellent procedural success and low in-hospital complication rates.
Activity of Platelets after Inhibition and Cardiovascular Events: Drug Eluting
Stent Implantation in Patients with Acute Coronary Syndrome Optical
Coherence Tomography Study: The APICE-OCT Study
Antonio Colombo, Alaide Chieffo, Guido Parodi, Ciro Indolfi, Bernhard Reimers,
Gill Louise Buchanan, Renato Valenti, Annalisa Mongiardo, Francesco Versaci,
Filippo Figini, Angela Migliorini, Carmen Spaccarotella, Salvatore Sacca’, Azeem
Latib, Renato Bianchi, Andrea Pacchioni, Angela Ferrari, David Antoniucci
Background: It has been reported that exposed stent struts are more frequent with first
generation drug eluting stent (DES). To our knowledge, no study has investigated the
rate of exposed (without neointimal coverage) stent struts in new generation DES in
acute coronary syndromes (ACS).
Methods: All eligible patients admitted to 4 Italian centers with ACS( STEMI,
NSTEMI or ACS with negative troponin) and a clinical indication for culprit lesion PCI
were randomized 1:1 to everolimus-(EES, Promus Element, Boston Scientific, Natick,
MA, USA) or zotarolimus-( ZES, Endeavor Resolute, Medtronic, Minneapolis, MN,
USA) eluting stents. Follow-up with OCT was performed at 6 months. The primary
study endpoint was the rate of exposed stent struts in EES vs.ZES evaluated by OCT.
Secondary endpoints were: the rate of malapposed stent struts, neointimal hyperplasia
(NIH) area and major adverse cardiac events (MACE) at 6 months.
Results: A total of 60 patients were enrolled. 83.3% were male with a mean age of 63.0
± 10.8 years and LVEF 51.7 ± 6.4%. Overall 31.7% of the patients presented with
STEMI, of these 63.2% in the anterior territory. Thrombus containing lesions were
present in 60.0%; in 23.3% of all patients thrombus aspiration was performed.
Glycoprotein IIb/IIIa inhibitors were used in 31.7% of the cases and bivalirudin in 16.7%.
The mean lesion length was 20.1 ± 9.7 mm. At 30-days clinical follow-up there was one
sudden cardiac death which occurred 8 days post index procedure, but no other MACE
reported. Six month MACE in addition to OCT analysis results will be presented.
Conclusion: Primary study end-point as well as secondary study endpoints will be
presented at the Scientific Sessions of TCT. 
Randomized Study to Assess the Effect of Thrombus Aspiration on Flow Area
in ST-Elevation Myocardial Infarction Patients: an Optical Frequency Domain
Imaging Study
Patrick Serruys, Yoshinobu Onuma, Leif Thuesen, Niels Ramsing Holm, Felix
Zijlstra, Robert-Jan van Geuns, Martin Van der Ent, Jean Fajadet, Gerhard Schuler,
Steffen Desch
Background: The use of thrombectomy devices during percutaneous coronary
intervention (PCI) in the setting of acute ST elevation myocardial infarction (STEMI)
has been recently shown to improve angiographic and clinical outcomes. The impact
of thrombus removal on acute luminal dimension is, however, still unclear. Removal
of thrombus before stenting could lead to better stent expansion, larger lumen and less
late malapposition. We hypothesize that primary PCI with thrombectomy will reduce
the thrombus burden, resulting in less intraluminal material and larger flow area than
primary PCI without thrombectomy.
Methods: This study is a prospective, randomized controlled, single blind, multi-centre
clinical study in 140 patients. Patients presenting with STEMI <12 hours from onset
of chest pain are randomized in a 1:1 fashion to either primary PCI with thrombectomy
or without thrombectomy. The primary endpoint is minimal flow area immediately
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after stenting assessed by Optical frequency domain tomography imaging (OFDI,
TERUMO Corporation, Tokyo, Japan) between the 2 treatment arms. Flow area is
defined as: (Stent area + incomplete stent apposition area) – (intraluminal defect area
attached to the wall + intraluminal defect area free from the wall). The sample size of
60 patients in each group would achieve 80% power to detect a difference of 0.72 mm2
in minimal flow area.
Results: As of July 31, 109 patients were enrolled. 72% of the enrolled patients were
male, 43% had current smoking habit, and 5% had diabetes mellitus. Treated vessels
were RCA in 35%, LCx in 14% and LAD in 41%. 23% of the patients were treated
using radial access. In some cases, OFDI documented a presence of significant amount
of intraluminal mass (Figure). The interim, blinded OFDI analysis of the first 62
patients showed the minimal flow area of 7.08±1.98 mm2 and mean flow area of
8.67±2.17 mm2.
Conclusion: The results of primary endpoint, the complete and unblinded OFDI
analysis of minimal flow area in the two groups will be presented at the meeting.
Prasugrel Versus Double Clopidogrel to Overcome Platelet Reactivity Early
Following a 600mg Clopidogrel Loading Dose In Patients Undergoing Primary
Percutaneous Coronary Intervention.
Dimitrios Alexopoulos, Ioanna Xanthopoulou, Konstantinos Theodoropoulos,
Georgios Kassimis, Ioannis Chiladakis, Periklis Davlouros, George Hahalis
Background: Platelet reactivity (PR) assessment in the very early phase (2 hours post
600mg clopidogrel loading dose-LD) of ST-elevation myocardial infarction (STEMI)
has not been previously reported nor any possible ways to overcome high on-treatment
PR (HTPR).
Methods: In STEMI patients undergoing primary PCI, PR was assessed with the
VerifyNow (Accumetrics Inc., San Diego, CA, USA) assay 2 hours after a 600mg
clopidogrel LD. Patients with HTPR (≥ 235 PR Units), were randomized to either
immediate reloading with 60mg prasugrel/10mg maintenance dose (MD) (group-A)
or clopidogrel 150mg MD starting from the next day (group-B). PR was re-assessed
at 2, 24 hours and at 5 days following randomization. Genotyping was performed for
CYP2C19*2 carriage.
Results: Out of 81 STEMI patients screened, 52(64.2%) demonstrated HTPR 2 hours
post LD and were all randomized (26 group-A and 26 group-B). PR at 2 hours, 24
hours and 5 days post randomization was lower in group- A compared to group-B
(Figure 1). HTPR rates were lower for group-A compared to group-B at 2 and 24 hours
post randomization (44.0% vs 76.9%, p=0.023 and 3.8% vs 61.5%, p<0.001
respectively) and marginally lower at 5 days post randomization (8.0% vs 30.8%,
p=0.075). HTPR rates were affected by CYP2C19*2 carriage mainly in group-B.
Conclusion: In STEMI patients, HTPR 2 hours following 600 mg of clopidogrel LD
is very common. An additional reloading with 60 mg of prasugrel followed by a 10 mg
MD, achieves greater platelet inhibition compared to clopidogrel 150 mg MD as early
as in 2 hours, a difference that is maintained up to 5 days. Complete genotyping
analysis will be presented. Platelet reacticity at 2, 24 hours and 5 days post
randomization.
The Evaluation of the Influence of Statins and Proton Pump Inhibitors on
Clopidogrel Antiplatelet Effect (SPICE) Trial
Jean-Pierre P. Dery, Ugo Déry, Stephane Rinfret, Eric Larose, Josep Rodes-Cabau,
Robert DeLarochellière, Mélanie Roy, Pierre-Louis Nadeau, Rodrigo Bagur, Helena
Tizon-Marcos, Louis Roy, Can M. Nguyen, Gerald Barbeau, Guy Proulx, Onil
Gleeton, Bernard Noel, Olivier F. Bertrand
Background: Previous pharmacodynamic studies have demonstrated that proton pump
inhibitors (PPI) and statins may interfere with the antiplatelet effect of clopidogrel.
Methods: SPICE was a single center prospective randomized open-label with blinded
endpoints trial. The primary objective was to compare the impact of 4 different anti-
acid therapies on the antiplatelet effect of clopidogrel. The secondary objective was to
determine which factors modulate this drug-drug interaction, including the choice of
statin and the presence of 2C19*2 polymorphism. After PCI, 320 patients were
randomized to rosuvastatin 20mg id or atorvastatin 80mg id. At 30 days, patients were
randomized again to either omeprazole 20mg id, pantoprazole 40mg id, esomeprazole
40mg id, or ranitidine 300mg id, stratified by statin group and 2C19*2 carrier state.
Platelet function tests were performed before and after 30 days of constant anti-acid
therapy. The study had 87% power to detect an absolute difference of 10% in the mean
change in maximal platelet aggregation (MPA) between two anti-acid groups in the
stratum of patients carrying the 2C19*2 polymorphism.
Results: As of August 1st, 319 patients have been recruited. Median age was 61 years.
Reason for PCI was ACS for 71% of patients. Thirty-day and 60-day platelet function
tests were available for 274 and 243 patients, respectively. After 30 days of anti-acid
therapy, MPA increased from 38.6% to 39.2% (p=0.8) in the ranitidine group and from
35.1% to 40.5% (p=0.0004) in the PPI groups combined. Similarly, platelet reactivity
index (VASP) increased from 44.9% to 47% (p=0.6) in ranitidine-treated patients and
from 42.8% to 49.6% p<0.0001) in PPI-treated patients. 
Conclusion: In patients receiving clopidogrel after PCI, concomitant anti-acid therapy
with proton-pump inhibitors decreased the antiplatelet effect of clopidogrel while the
H2 receptor blocker ranitidine had no impact on platelet reactivity. The differential
effect of each PPI and the role of the choice of statin and 2C19*2 polymorphism on this
drug-drug interaction will be presented at the meeting.
Vasoreactivity Results of Cohort 1 at Six Month Post Implantation of the Drug
Eluting Absorbable Metal Scaffold in the BIOSOLVE-I Study
Raimund Erbel, Dirk Böse, Michael Haude, Hubertus Degen, Stefan Verheye, Paul
Vermeersch, Paul Erne, Ron Waksman, Jacques Koolen
Background: Absorbable metal scaffolds (AMS) were developed for the treatment of
coronary artery stenosis. The major advantages of AMS after bioabsorption, are that
they only leave behind the natural healed vessel within 6 -12 months post implantation.
Most recently a new drug (Paclitaxel) eluting AMS (DREAMS) was developed to
reduce the revascularization rates. The aim of this substudy was to evaluate the
restoration of vasoreactivity 6 months post implantation.
Methods: BIOSOLVE-I is a prospective, multicenter first in man trial for the
evaluation of DREAMS in the treatment of coronary stenosis with follow-up
investigations at 1, 6, 12, 24 and 36 months. Vasomotion test was performed at a
subgroup of the patients during 6 month follow-up at two study sites. Endothelium
dependent vasoactive agent acetylcholine (ACH) was administered intracoronary in
different doses (0.36 µg/mL, 3.6 µg/ml and 18 µg/mL) in order to evaluate
vasoreactivity during follow-up. Quantitative coronary angiography was done to assess
coronary dimensions during vasomotion testing.
Results: Vasomotion test was performed in 14 patients (11 males/3 females) of cohort
1 with a mean age of 65.6 ± 10.0 years. Hypertension (92.9%), hyperlipidemia (85.7%),
were the major cardiovascular risk factors and history of myocardial infarction was
present in 42.9% of the subjects. Type A (50.0%), Type B1 (42.9%) and Type B2 (7.1%)
lesions were treated with a 3.25 / 16mm (50.0%) or a 3.5 / 16mm (50.0%) DREAMS.
During 6 month follow-up the mean lumen diameter was 2.55 ± 0.8mm in the treated
segment and 2.64 ± 0.96mm and 2.40 ± 0.66mm in the proximal and distal reference
segment. After infusion of ACH, the lumen dimensions decreased to 2.25 ± 0.9mm in
the treated segment and 2.42 ± 0.95mm and 2.08 ± 0.82mm in the reference segments.
Conclusion: Coronary arteries undergoing DREAMS implantation regains vasomotor
function at the treated segment at 6 months as reflected by vasoconstriction of the
scaffold segment. These observations support scaffolding bioabsorption with
restoration of vessel vasoreacitivity.
Comparison of Resolute Zotarolimus-Eluting Stent and Sirolimus-Eluting
Stents in Patients with Long Coronary Artery Lesions: A Randomized LONG-
DES IV Trial
Young-Hak Kim, Duk-Woo Park, Won-Jang Kim, Jong-Young Lee, Soo-Jin Kang,
Seung-Whan Lee, Cheol-Whan Lee, Seong-Wook Park, Sung Yun Lee, Bong Ki Lee ,
Jang-Hyun Cho, Tae-Hyun Yang, Nae-Hee Lee, Joo-Young Yang, Jong-Seon Park,
Won-Yong Shin, Moo Hyun Kim, Jang Ho Bae, Myeong-Kon Kim, Junghan Yoon,
Seung-jung Park
Background: Outcomes remain relatively unfavorable for stent-based coronary
intervention of lesions with long diseased segments.
Methods: This randomized, multicenter, prospective trial compared the Resolute
zotarolimus-eluting stents (ZES) and sirolimus-eluting stents (SES) in 500 patients
with long (≥25 mm) native coronary lesions. The primary end point of the trial was in-
segment late luminal loss at 9 months angiographic follow-up.
Results: The ZES and SES groups had similar baseline characteristics. Lesion length
was 32.4±13.5 mm in the ZES group and 31.0±13.5 mm in the SES group (P=0.27).
Nine-month angiographic follow-up was performed in 70% of eligible patients. In-
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